12:00 AM
 | 
May 08, 2006
 |  BioCentury  |  Emerging Company Profile

Cardiokine: (Vaso)pressin ahead

After closing a $50 million series B round last week, Cardiokine Inc. has now raised a total of $87 million on the strength of a single product: Lixivaptan, a once-shelved hyponatremia candidate in-licensed from Wyeth in 2004. The company plans to start Phase III testing of the selective vasopressin V2 receptor antagonist this summer.

Co-founder and Chairman James Mervis said Cardiokine’s initial goal was to go around "knocking on doors" at big pharma looking for a product around which it could build and finance the company. In 2004, the search turned up a shelved project at WYE (Madison, N.J.) that met Cardiokine’s wish list (see BioCentury, April 19, 2004).

For one thing, Mervis...

Read the full 564 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >